



Supplementary Reading Materials

1. Brady, L. S., Potter, W. Z., & Gordon, J. A. (2019). Redirecting the Revolution: New developments in drug development for psychiatry. *Expert Opinion on Drug Discovery*, 14(12), 1213-1219. <https://doi.org/10.1080/17460441.2019.1666102>
2. Clayton, A. R. (2019). My Struggle to Access Lifesaving Mental Health Care. *Health Affairs*, 38(4). <https://doi.org/10.1377/hlthaff.2018.05354>
3. Krogmann, A., Peters, L., Von Hardenberg, L., Bödeker, K., Nöhles, V., & Correll, C. (2019). Keeping up with the therapeutic advances in schizophrenia: A review of novel and emerging pharmacological entities. *CNS Spectrums*, 24(S1), 38-69. <https://doi.org/10.1017/S109285291900124X>
4. Małgorzata, P., Paweł, K., Iwona, M. L., Brzostek, T., & Andrzej, P. (2020). Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets. *Expert Opinion on Therapeutic Targets*, 24(12), 1187-1209. <https://doi.org/10.1080/14728222.2020.1836160>
5. Mantas, I., Saarinen, M., Xu, ZQ. D., & Svenningsson, P. (2021). Update on GPCR-based targets for the development of novel antidepressants. *Molecular Psychiatry*. <https://doi.org/10.1038/s41380-021-01040-1>
6. Sonnenschein, S. F. & Grace, A. (2021). Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis. *Expert Opinion on Therapeutic Targets*, 25(1), 15-26. <https://doi.org/10.1080/14728222.2021.1849144>
7. Ved, H. S. & Doshi, G. M. (2020). A Review on Emerging Drug Targets in Treatment of Schizophrenia. *Current Drug Targets*, 21(15), 1593-1605. DOI: 10.2174/1389450121666200615150429
8. Wilkinson, S. T. & Sanacora, G. (2019). A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. *Drug Discovery Today*, 24(2), 606-615. <https://doi.org/10.1016/j.drudis.2018.11.007>